ROCR Value Based Program Act

The ROCR Value Based Program Act (S.1031) was introduced in the Senate on March 13, 2025, by Sen. Tillis (R-NC) with four cosponsors, and referred to the Committee on Finance. It has a House companion bill (HR2120). The bill proposes replacing the current fee-for-service Medicare payment structure for radiation oncology with episode-based bundled payments, where a single payment covers the entire course of radiation therapy for a cancer patient rather than paying per procedure. The bill also includes a new exception for free or discounted patient transportation. The money trail is nonexistent at this stage — the bill authorizes no funding, and any future Medicare payment changes would affect the roughly $4.2 billion in annual Medicare spending on radiation oncology services cited in the bill's findings. Authorization by this bill would set policy, but actual implementation requires CMS rulemaking and does not involve direct federal spending through appropriations. Structural winners and losers: If enacted, this bill is structurally bearish for capital equipment vendors that sell linear accelerators, CT simulators, and radiation therapy planning systems to U.S. hospitals and freestanding centers. GE HealthCare ($GEHC) is the most directly affected publicly traded pure-play, as its imaging and precision care businesses include radiation oncology equipment. Varian Medical Systems (now part of Siemens Healthineers, which trades OTC as $SMMNY) is a more exposed pure-play but not listed on a U.S. exchange. Diversified hospital operators like HCA Healthcare ($HCA) and Tenet ($THC) would face margin compression from bundled payments reducing per-procedure revenue, though volume effects could offset this. Real market data confirms $GEHC is already under severe pressure: trading at $59.66 as of April 30, 2026, down 13.3% in the last 7 days and 16.2% in the last 30 days. The stock is just $0.91 above its 52-week low of $58.75. The current selloff appears driven by broader market or sector factors (medical device selloffs, earnings, or macro) rather than this bill, which has not advanced since introduction. Timeline: The bill has had zero legislative action since referral to the Senate Finance Committee 13 months ago. With 4 cosponsors and a companion bill in the House, it has some bipartisan support but no committee markups scheduled. The 119th Congress runs through January 2027, so the window for passage is contracting. Measurable market impact would only occur if the bill advances to committee hearings or a CBO score, which has not happened.